<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is a clonal disease of the bone marrow characterized by <z:mp ids='MP_0002123'>abnormal hematopoiesis</z:mp> and cytopenias </plain></SENT>
<SENT sid="1" pm="."><plain>It has been shown that abnormal cytokine production together with <z:mpath ids='MPATH_3'>apoptosis</z:mpath> are major contributors to the cytopenias associated with the disorder </plain></SENT>
<SENT sid="2" pm="."><plain>As the interaction of cytokines plays a role in the pathogenesis, suppression of the cytokine production by the administration of the combination of pentoxifylline, ciprofloxacin, and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> (PCD combination) has resulted in the correction of at least some aspects of the cytopenias in the majority of patients and in complete hematologic remission in a small percentage </plain></SENT>
<SENT sid="3" pm="."><plain>The aminothiol <z:chebi fb="0" ids="50266">prodrug</z:chebi> <z:chebi fb="0" ids="2636">amifostine</z:chebi>, a compound to protect tissues from cytotoxic drugs and radiotherapy has been found to stimulate proliferation of <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis and suppress <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In this study we report the results of combination therapy of <z:chebi fb="0" ids="2636">amifostine</z:chebi> and PCD in 12 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="2636">Amifostine</z:chebi> was given in a dose of 200 mg/m(2), as an i.v. infusion administered in 10 min, three times a week; pentoxifylline 2400 mg/day, (3 x 800 mg) p.o.; ciprofloxacin, 1 g/day p.o.; <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> 4.5 mg/day p.o </plain></SENT>
<SENT sid="6" pm="."><plain>We achieved 66% response rate in our patients </plain></SENT>
<SENT sid="7" pm="."><plain>In some cases responses were achieved in only <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> or <z:hpo ids='HP_0001903'>anemia</z:hpo> whereas in others responses were achieved in multiple series </plain></SENT>
<SENT sid="8" pm="."><plain>As a result it was found that <z:chebi fb="0" ids="2636">amifostine</z:chebi> + PCD combination may be beneficial in reversing cytopenias in the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and is worth further study </plain></SENT>
</text></document>